Trending...
- Root Canal Specialist In Frederick Maryland Joins Pearlfection Dentistry
- Rep. Gina H. Curry and Dr. Conan Tu Inspire at Kopp Foundation for Diabetes Hybrid Fundraising Gala and National Leadership Forum
- TopicInDetail.com Unveils "Do it Free AI" – AI Powered Search Engine That Gives You Plan and Resources To do anything
PHILADELPHIA, June 18, 2021 /PRNewswire/ -- It's long been known that people living with HIV experience a loss of white matter in their brains. As opposed to gray matter, which is composed of the cell bodies of neurons, white matter is made up of cells that produce myelin, a fatty substance that coats neurons, offering protection and helping them transmit signals efficiently. A reduction in white matter is associated with motor and cognitive impairment.
Earlier work by a team from Penn Dental Medicine and Children's Hospital of Philadelphia (CHOP) found that antiretroviral therapy (ART)—the lifesaving drugs that many with HIV use daily—can reduce white matter, but it wasn't clear how the virus itself contributed to this loss.
In a new study using both human and rodent cells, the team has determined how HIV prevents the myelin-making brain cells called oligodendrocytes from maturing, reducing white matter production. When the researchers applied a compound blocking to this process, the cells were once again able to mature. The work appears in the journal Glia.
More on The PennZone
"Even when people with HIV have their disease well-controlled by antiretrovirals, they still have the virus present in their bodies, so this study came out of our interest in understanding how HIV infection itself affects white matter," says Kelly Jordan-Sciutto, professor at Penn Dental Medicine and the study's co-senior author. "By understanding those mechanisms, we can take the next step to protect people with HIV from these impacts."
Jordan-Sciutto and Judith Grinspan, CHOP research scientist and Professor of Neurology at Penn Medicine, have been collaborating to elucidate how ART and HIV affect the brain. Their previous work on antiretrovirals had shown that commonly used drugs disrupted the function of oligodendrocytes, reducing myelin formation.
More on The PennZone
In the current study, they aimed to isolate the effect of HIV on this process by looking at human macrophages, one of the major cell types that HIV infects.
Ultimately, the researchers want to discern the effects of the virus from the drugs used to treat it in order to better evaluate the risks of each.
"When we put people on ART, it's important to understand the implications," says Jordan-Sciutto. "Antiretrovirals may prevent the establishment of a viral reservoir in the central nervous system, which would be wonderful, but we also know some drugs have unintended consequences, which may include altering white matter." Read more on the study >>
Contact: Beth Adams, [email protected]
SOURCE Penn Dental Medicine
Related Links
http://www.dental.upenn.edu
Earlier work by a team from Penn Dental Medicine and Children's Hospital of Philadelphia (CHOP) found that antiretroviral therapy (ART)—the lifesaving drugs that many with HIV use daily—can reduce white matter, but it wasn't clear how the virus itself contributed to this loss.
In a new study using both human and rodent cells, the team has determined how HIV prevents the myelin-making brain cells called oligodendrocytes from maturing, reducing white matter production. When the researchers applied a compound blocking to this process, the cells were once again able to mature. The work appears in the journal Glia.
More on The PennZone
- Phinge Announces "Test the Waters" Campaign for Potential Regulation A+ Offering: Home of Netverse Verified AI & Patented App-less Technology Platform
- RJ Grimshaw Launches "The AI EDGE" A Practical Guide Where Leadership Meets Innovation
- Probate Shepherd® Announces a New Member Probate Attorney in Sugar Land, TX
- Unconventional Storytelling: The Offbeat Charm of an Intersectional Narrative
- New Premier Indoor Golf Destination: "The Golf Place" Grand Opening Set 10/25
"Even when people with HIV have their disease well-controlled by antiretrovirals, they still have the virus present in their bodies, so this study came out of our interest in understanding how HIV infection itself affects white matter," says Kelly Jordan-Sciutto, professor at Penn Dental Medicine and the study's co-senior author. "By understanding those mechanisms, we can take the next step to protect people with HIV from these impacts."
Jordan-Sciutto and Judith Grinspan, CHOP research scientist and Professor of Neurology at Penn Medicine, have been collaborating to elucidate how ART and HIV affect the brain. Their previous work on antiretrovirals had shown that commonly used drugs disrupted the function of oligodendrocytes, reducing myelin formation.
More on The PennZone
- Live Good Leads with Love: Creating Opportunity, Protecting the Vulnerable and Inspiring Hope
- Probate Shepherd® Announces a New Member Probate Attorney in The Woodlands, TX
- Probate Shepherd® Announces a New Member Probate Attorney in Conroe, TX
- Taraji P. Henson's Boris Lawrence Henson Foundation (BLHF) Announce 5th Annual Can We Talk? Arts & Wellness Summit and "i AM The Table Benefit Brunch
- Bright Hope Baptist Church Fall Bazaar - A Day of Community, Creativity, and Celebration
In the current study, they aimed to isolate the effect of HIV on this process by looking at human macrophages, one of the major cell types that HIV infects.
Ultimately, the researchers want to discern the effects of the virus from the drugs used to treat it in order to better evaluate the risks of each.
"When we put people on ART, it's important to understand the implications," says Jordan-Sciutto. "Antiretrovirals may prevent the establishment of a viral reservoir in the central nervous system, which would be wonderful, but we also know some drugs have unintended consequences, which may include altering white matter." Read more on the study >>
Contact: Beth Adams, [email protected]
SOURCE Penn Dental Medicine
Related Links
http://www.dental.upenn.edu
Filed Under: Business
0 Comments
Latest on The PennZone
- First Nations Bank of Canada Partners with KYC2020 to Strengthen AML Screening and Monitoring Capabilities
- Phillies' Bats Wake in Game 3: Turner, Schwarber, Harper, Bohm Fuel 8-2 NLDS Victory Over Dodgers
- Bitcoin will still be the leader in the cryptocurrency market in 2025, and WOA Mining enthusiasts will earn passive income
- Triumph Thru Tears Premieres at 55th Anniversary Pamoja Celebration at the University of Georgia
- Helping Haircare Brands Launch with Confidence: Bond & Bloom Innovation Group Leads in Product Development
- Holiday Fineries at the Wineries on the Shawangunk Wine Trail
- Chadwick Twillman Demands Resignation of MLive Editor Joey Oliver for Publishing Deceptive Hit Piece
- Smile More Implant Centre Launches Cutting-Edge Website
- K2 Integrity Names Aaron Karczmer Chief Executive Officer
- Georgia's Lanier Islands Resort Announces Return of Magical Nights of Lights
- Boston Industrial Solutions' Natron® XG Series Ink Exceeds Global Safety Compliance
- West Virginia Grassroots Group Sparks Statewide Momentum in the Fight for Election Integrity
- Chaos and Clarity: OddsTrader's Latest College Football Playoff Predictions After Week 6
- Bookmakers Review Highlights Five Intriguing Bets to Make in October 2025
- Bent Danholm Partners with JamesEdition to Bring Central Florida Luxury Homes to a Global Stage
- Racing Star Robert Noaker Returns Home for Meet & Greet at Maguire's Ford of Duncannon
- $500K Share Dividend and AI-Cybersecurity Breakthrough in $500B Market Through Strategic Partnership with Cycurion $CYCU: iQSTEL (N A S D A Q: IQST)
- QikBIM launches to Revolutionize Architectural Design, Expands into Asset-Backed Real Estate with $100 Million Capital OFA Group: (N A S D A Q: OFAL)
- Costa Oil – 10 Minute Oil Change: 2025 Franchisee of the Year Award
- Five Years of Impact: New Jersey Arts & Culture Renewal Fund Celebrates Milestone Anniversary